There is widespread hope for curbing HIV after the United States Food and Drug Administration (FDA) approved an injectable ...

This new FDA-approved shot is designed to break down the barriers that have kept too many people from accessing PrEP.

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

Current operations chief Renee Gala will succeed Bruce Cozadd at Jazz. Meanwhile, a key study of an Ultragenyx and Mereo drug ...

The Global Fund has announced that it signed an access agreement with Gilead Sciences to procure lenacapavir, a twice-a-year injection that has a 99 per cent success rate in preventing HIV ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Gilada, the only Indian serving on the International AIDS Society (IAS) Governing Council, assured the country has the ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

About 17,000 people are set to benefit from free access to the long-acting HIV prevention injection, lenacapavir, which only needs to be administered twice a year. This follows a new ...

Trump administration funding cuts and dismantling of USAID force a shift from HIV elimination back to treatment.

Funding cuts to the global HIV response could trigger a surge of 6 million new infections and 4 million AIDS-related ...